Compare Amylx Pharmaceuticals Inc (AMLX) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Roundhill Magnificent Seven ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Roundhill Magnificent Seven ETF trades at $67.39. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | MAGS | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Sector/Thematic |
52-Week High | $18.70 | $70.94 |
52-Week Low | $7.64 | $55.39 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MAGS trades at $67.68, up 1.38% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF holds equal-weighted Magnificent Seven stocks, offering concentrated mega-cap tech exposure. Recent news highlights AI-driven volatility and debates over concentration risks versus growth potential, with the fund up 181% since launch but facing 2026 headwinds as AI profits outside tech remain uncertain.
Outlook hinges on AI adoption and interest rate trends, with small-cap rotation posing a risk. Opportunities include hyperscaler valuation compression and quarterly rebalancing. Key risks are overconcentration in tech, regulatory scrutiny, and macroeconomic shifts affecting growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
